Table 1.
Baseline characteristics at admission, interventions, and mortality of patients admitted to ICU with SARS-Cov 2 pneumonia. Differences between patients according to each wave
| Characteristics | All Patients | Wave 1 (N = 51) | Wave 2 (N = 133) | Wave 3 (N = 191) | Wave 4 (N = 62) | P-value |
|---|---|---|---|---|---|---|
| Patients | ||||||
| Age, years, median (Q1;Q3) | 65 (55;72) | 65 (56;72) | 68 (60;75) | 66 (56;72) | 57 (45;65) | < 0.001 |
| Male, n (%) | 309 (71%) | 36 (71%) | 107 (81%) | 124 (65%) | 42 (68%) | 0.0241 |
| Charlson score, median (Q1;Q3) | 1 (0;2) | 1 (0;3) | 1 (0;3) | 1 (0;3) | 0 (0;1) | 0.0085 |
| Chronic kidney disease, n(%) | 39 (9%) | 10 (20%) | 9 (7%) | 18 (9%) | 2 (3%) | 0.0129 |
| BMI, kg/m2, median (Q1;Q3) | 28 (25;32) | 26 (23;29) | 28 (25;33) | 28 (26;31) | 29 (27;33) | 0,00109 |
| ICU admission | ||||||
| SAPS II, median (Q1;Q3) | 32 (22;44) | 41 (31;49.5) | 40 (29;51) | 30 (21;40) | 24 (17;30.5) | < 0.001 |
| SOFA, median (Q1;Q3) | 4 (2;7) | 7 (4.5;9) | 4 (2;7) | 3 (2;7) | 3 (2;6) | < 0.001 |
| PaO2/FiO2 ratio, median (Q1;Q3) | 147 (106;182) | 146 (110;164) | 160 (113;200) | 137 (100;174) | 150 (116;165) | 0,09 |
| D-dimer, ng/mL, median (Q1;Q3) | 990 (594;1867) | 1138 (787;1774) | 865 (492;1626) | 1041 (681;1963) | 899 (527;1480) | 0.0246 |
| Lactates, mmol/L, median (Q1;Q3) | 1,3 (1,0;1,7) | 1,3 (1,0;1,7) | 1,3 (1,0;1,7) | 1,3 (1,0;1,7) | 1,3 (1,0;1,5) | 0,618 |
| CRP, mg/L, median (Q1;Q3) | 141 (84;216) | 238 (152;303) | 160 (93;228) | 123 (77;199) | 120 (73;178) | 8,35.10–8 |
| Lymphocytes, 109/L, median (Q1;Q3) | 0,7 (0,5;0,92) | 0,68 (0,5;0,98) | 0,69 (0,46;0,86) | 0,71 (0,51;0,92) | 0,77 (0,59;1) | 0,119 |
| ICU stay | ||||||
| MV, n (%) | 282 (65%) | 46 (90%) | 87 (65%) | 114 (60%) | 35 (57%) | < 0.001 |
| duration (n = 280), days, median (Q1;Q3) | 9 (5;20) | 6 (3;11) | 9 (5;19) | 12 (6;22) | 11 (7;28) | < 0.001 |
| Vasopressors a, n (%) | 48 (11%) | 15 (30%) | 4 (8%) | 4 (8%) | 5 (10%) | < 0.001 |
| Dexamethasone, n (%) | 357 (82%) | 0 (0%) | 133 (98%) | 167 (87%) | 60 (97%) | < 0.001 |
| AKI, n (%) | 135 (31%) | 26 (51%) | 49 (37%) | 49 (26%) | 12 (19%) | < 0.001 |
| RRT, n (%) | 54 (12%) | 16 (31%) | 9 (7%) | 24 (13%) | 5 (8%) | < 0.001 |
| ECMO, n (%) | 8 (2%) | 2 (4%) | 1 (1%) | 4 (2%) | 1 (2%) | 0,534 |
| VAP, n (%) | 170 (39%) | 13 (26%) | 55 (41%) | 76 (40%) | 26 (42%) | 0,795 |
| CAPA, n (%) | 22 (5%) | 3 (6%) | 8 (6%) | 7 (4%) | 4 (7%) | 0,717 |
| ICU LOS, days, median (Q1;Q3) | 8 (4;15) | 8 (4;14) | 8 (4;15) | 8 (4;16) | 7 (4;15) | 0,945 |
| Hospital LOS, days, median (Q1;Q3) | 20 (12;33) | 18 (10;39) | 18 (11;29) | 22 (14;34) | 19 (12;35) | 0,19 |
| Mortality, n (%) | ||||||
| In ICU | 53 (12%) | 13 (26%) | 13 (10%) | 20 (11%) | 7 (11%) | 0.0209 |
| In-hospital | 68 (16%) | 17 (33%) | 15 (12%) | 28 (15%) | 8 (14%) | 0.0037 |
SAPSII simplified acute physiologic score, SOFA sequential organ failure assessment, AKI acute kidney injury, MV mechanical ventilation, RRT renal replacement therapy, ECMO extracorporeal membrane oxygenation, VAP ventilated associated pneumonia, CAPA covid19 associated pulmonary aspergillosis, LOS length of stay
anorepinephrine > 0.3µg/kg/min